SCHEMBL126092

SCHEMBL126092

O=c1[nH]ccc2occc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 4/20 0.42
MAOA P21397 2/20 0.42
MAOB P27338 2/20 0.42
FTO Q9C0B1 2/20 0.42
GSK3B P49841 2/20 0.41
NFKB1 P19838 1/20 0.40
ALDH1A1 P00352 4/20 0.38
CYP3A4 P08684 3/20 0.38
HPGD P15428 3/20 0.38
KDM4E B2RXH2 2/20 0.38
CYP1A2 P05177 2/20 0.38
HSD17B10 Q99714 2/20 0.38
LMNA P02545 1/20 0.38
CYP2C9 P11712 1/20 0.38
RAB9A P51151 1/20 0.38
BLM P54132 1/20 0.38
PARP15 Q460N3 1/20 0.38
RECQL P46063 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
HTR2C P28335 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4420524 0.68 HTR2C (0.37) PARP1MAOAMAOBFTONFKB1
SCHEMBL216625 0.67
SCHEMBL4429415 0.67 PAX8 (0.48) MAOAMAOBFTONFKB1ALDH1A1
SCHEMBL23219216 0.67 MAOA (0.42) MAOAMAOBFTONFKB1HTR2C
SCHEMBL29591435 0.67 MAOA (0.42) MAOAMAOBFTONFKB1HTR2C
SCHEMBL11480070 0.67 GSK3B (0.42) PARP1GSK3BALDH1A1CYP3A4HPGD
SCHEMBL14221224 0.65 CYP3A4 (0.39) MAOAMAOBFTONFKB1ALDH1A1
SCHEMBL16564370 0.65 GSK3B (0.53) PARP1GSK3BALDH1A1CYP3A4HPGD
SCHEMBL1238307 0.65 GSK3B (0.53) PARP1GSK3BALDH1A1CYP3A4HPGD
SCHEMBL8861466 0.65 PARP1 (0.52) PARP1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116284019-B Preparation method of medical intermediate furo [3,2-c ] pyridine-4 (5H) -ketone derivative 安徽工业大学 2024-08-09 CN claimed
CN-116284019-A Preparation method of medical intermediate furo [3,2-c ] pyridine-4 (5H) -ketone derivative 安徽工业大学 2023-06-23 CN claimed
US-12545700-B2 Excitonic quantum computing via aggregate-aggregate coupling BOISE STATE UNIVERSITY (US) 2026-02-10 US disclosed
EP-4674855-A1 A COMPOUND, AN ORGANIC LIGHT EMITTING DIODE COMPRISING THE DERIVATES, A USE OF THE DIODE, AND A CONSUMER PRODUCT Noctiluca S.A. (PL) 2026-01-07 EP disclosed
US-12479998-B2 Dyes in dye aggregate systems—engineering J, K, and dye packing BOISE STATE UNIVERSITY (US) 2025-11-25 US disclosed
EP-4592297-A1 AN ORGANIC BORON COMPOUND, AN ORGANIC LIGHT EMITTING DIODE COMPRISING THE ORGANIC BORON COMPOUND, A USE OF THE DIODE, AND A CONSUMER PRODUCT Noctiluca S.A. (PL) 2025-07-30 EP disclosed
WO-2025092905-A1 PARP INHIBITORS AND USES THEREOF SUZHOU EOC MEDICAL RESEARCH CO., LTD. (CN) 2025-05-08 WO disclosed
US-12292668-B2 Molecular aggregate for optically-pumped nonreciprocal exciton devices BOISE STATE UNIVERSITY (US) 2025-05-06 US disclosed
CN-114096540-B Translocation control elements, reporter codes and other means for translocation control for nanopore sequencing 豪夫迈·罗氏有限公司 2025-04-22 CN disclosed
CN-119431381-A Heterocyclic compounds and application thereof 上海艾力斯医药科技股份有限公司 2025-02-14 CN disclosed
US-20250002497-A1 IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION BRISTOL MYERS SQUIBB CO (US) 2025-01-02 US disclosed
WO-2002062816-A1 NON-NATURAL NUCLEOTIDES AND DINUCLEOTIDES CELLTECH R & D LIMITED (GB) 2002-08-15 WO disclosed
US-6399616-B1 4-(4-(2-(5-(1,2,4-TRIAZOL-1-YLMETHYL)-1H-INDOL-3-YL)ETHYL)-1 -PIPERAZINYL)FURO(3,2-C)PYRIDINE; COMBINED SEROTONIN REUPTAKE INHIBITOR AND PARTIAL AGONIST OF 5-HT RECEPTORS; REDUCED LATENCY; DEPRESSION LES LABORATOIRES SERVIER (FR) 2002-06-04 US disclosed
EP-1078928-A1 Pyridine derivatives, process for their preparation and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 2001-02-28 EP disclosed
US-5206365-A Psychotropic heterobicycloalkylpiperazine derivatives NEW JAMES S (US) 1993-04-27 US disclosed
US-5116970-A Tranquilizers NEW JAMES S (US) 1992-05-26 US disclosed
US-5001130-A 1-((Amide-containing bicyclic hetero ring)-butyl-),4-heterocyclic-piperazine; anxiolytic agents; psychological disorders BRISTOL-MYERS COMPANY (US) 1991-03-19 US disclosed
EP-0329168-A2 Psychotropic heterobicycloalkylpiperazine derivatives Bristol-Myers Squibb Company (US) 1989-08-23 EP disclosed
US-4808595-A REDUCTION OF PRESSURE DUE TO GLAUCOMA MERCK & CO., INC. (US) 1989-02-28 US disclosed
EP-0271273-A2 Thieno-and furopyridine sulfonamides MERCK & CO. INC. (US) 1988-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12545700-B2 Excitonic quantum computing via aggregate-aggregate coupling ELAVL1, ELAVL3, NCAPH PARP1 416/4885MAOA 4194/4885MAOB 4402/4885
US-20250002497-A1 IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION F2RL3, F2R, TMPRSS4 PARP1 430/4885MAOA 2780/4885MAOB 2563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.